GRCE
Grace Therapeutics, Inc.
$2.45
+0.01 (+0.41%)
At close · Jul 10
Market Cap
$39.87M
Shares
16,274,026
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.45
Open$2.47
Day$2.37–2.52
52W$1.79–5.18
Avg vol 30d283K
Short int1.7M · 10.5% float · 5.1d
Short vol49%
Last earningsFeb 14, 2023
DataJan 2020–Jul 2026
Filing10-K · Jun 18
Up next
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Jun 18, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
+5%
above
RSI (14)
53
neutral
MACD trend
Positive
52-week position
19%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−33%
trailing
YTD return
−29%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+59% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.48% of float · ▼ -10.4% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 1-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
EPS growth
+41%
Y/Y
Balance sheet
$17.0M
net cash
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
+5%
Bullish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
19%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+59% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.48% of float · ▼ -10.4% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 19%
52-wk high $5
vs 200-day avg -25%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRCE
this stock
Grace Therapeutics, Inc.
|
$39.87M | -29.2% | -100.0% | — | 10.5% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRCE | +3.4% | +6.1% | -32.7% | +7.9% | -29.2% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +2.0% | +2.0% | -41.8% | +6.8% | -39.9% |